Liquid biopsies represent a non-invasive method for detecting and monitoring cancer. By analyzing circulating tumor DNA (ctDNA) in blood samples, liquid biopsies can provide valuable insights into the genetic makeup of tumors. This technology offers potential for early detection, real-time monitoring of treatment efficacy, and identification of resistance mechanisms, making it a powerful tool in precision oncology.
